UP!

SRPT $112.48

SRPT target price
112.48
0
0

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980, the company maintains some laboratory capability in Corvallis, Oregon. As of 2014, the company does not commercialize any approved drug. As of 2008, Sarepta has 170 issued medical patents, and over 150 patents pending. The company changed its name from AVI BioPharma and stock symbol from AVII in July 2012 to Sarepta Therapeutics and SRPT respectively.

At its founding in 1980, the company was named AntiVirals, Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis, Oregon, in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit nor developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won a $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time the company had completed its headquarters move to Bothell.

In 2012 the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.

Its primary products are Morpholino oligomers (PMOs), synthetic nucleic acid analogs that were conceived of by James Summerton and invented by Summerton with Dwight Weller, and are being developed under the name NeuGene Antisense. Since morpholino oligomers can form sequence-specific double-stranded complexes with RNA they are suitable use in antisense therapy. In one application, translation blocking, a morpholino oligomer binds to messenger RNA produced by a known disease-causing gene to prevent it from being translated into protein. Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, Duchenne muscular dystrophy (DMD), and infectious diseases. Their greatest success thus far has been in DMD and as antiviral agents.

The Morpholino drug eteplirsen, targeting exon 51 of the dystrophin mRNA, has been approved as a human therapeutic by the FDA in 2016 and clinical trials for Morpholinos targeting other exons are ongoing. Morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses, including influenza, West Nile Virus, SARS, Hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. They are in advanced development for prevention and treatment of Ebola and Marburg viruses. In March 2013, the Company announced positive results from a non-human primate study of AVI-7288, the drug candidate for treatment of Marburg virus infection. The results showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in monkeys exposed to this fatal virus. These results are similar to those in previous studies when the drug was given by intravenous injection.

In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-01 Future report Set alerts
Q2 2022 2022-08-02 -2.65 -2.65
Q1 2022 2022-05-04 -1.20 -1.20
Q4 2021 2022-03-01 -1.42 -1.42
Q3 2021 2021-11-03 -0.60 -0.60
Q2 2021 2021-08-04 -1.02 -1.02
Q1 2021 2021-05-05 -2.10 -2.10
Q4 2020 2021-03-01 -2.40 -2.40
Q3 2020 2020-11-05 0.00 0.00
Q2 2020 2020-08-05 -1.93 -1.93

Ratings

2016-06-27 Reiterated Rating Robert W. Baird Outperform $23.00
2016-06-27 Reiterated Rating William Blair Market Perform
2016-06-25 Reiterated Rating Jefferies Group Underperform $7.00
2016-06-22 Reiterated Rating Wedbush Outperform $36.00
2016-06-21 Reiterated Rating Oppenheimer Outperform $60.00
2016-06-21 Reiterated Rating Oppenheimer Holdings Inc. Outperform $60.00
2016-06-10 Reiterated Rating Robert W. Baird Buy
2016-06-09 Upgrade Piper Jaffray Underweight to Neutral
2016-06-09 Upgrade Piper Jaffray Cos. Underweight to Neutral
2016-06-08 Reiterated Rating WBB Securities Buy $40.00
2016-06-07 Upgrade Wedbush Neutral to Outperform $14.00 to $36.00
2016-06-07 Reiterated Rating Janney Montgomery Scott Hold
2016-06-07 Reiterated Rating Cowen and Company Hold
2016-06-04 Reiterated Rating Piper Jaffray Sell $6.00
2016-06-03 Reiterated Rating JMP Securities Sell $10.00
2016-06-03 Reiterated Rating Oppenheimer Outperform $60.00
2016-06-03 Reiterated Rating RBC Capital Hold $5.00
2016-06-03 Reiterated Rating Robert W. Baird Outperform $23.00
2016-06-03 Reiterated Rating Leerink Swann Underperform $5.00
2016-06-03 Reiterated Rating Royal Bank Of Canada Hold $5.00
2016-06-02 Reiterated Rating Jefferies Group Sell $7.00
2016-06-01 Reiterated Rating Wedbush Outperform $14.00 to $23.00
2016-05-27 Reiterated Rating SunTrust Reduce
2016-05-27 Reiterated Rating SunTrust Banks Inc. Reduce
2016-05-26 Reiterated Rating Robert W. Baird Outperform $23.00
2016-05-26 Reiterated Rating Oppenheimer Outperform $60.00
2016-05-26 Reiterated Rating Leerink Swann Sell
2016-05-26 Reiterated Rating Janney Montgomery Scott Hold
2016-05-26 Reiterated Rating Piper Jaffray Sell
2016-05-26 Reiterated Rating Cowen and Company Hold
2016-05-26 Reiterated Rating RBC Capital Sector Perform $5.00
2016-05-25 Reiterated Rating Wedbush Neutral $14.00
2016-05-08 Reiterated Rating Robert W. Baird Buy
2016-05-06 Reiterated Rating Jefferies Group Sell $7.00
2016-05-05 Downgrade Ladenburg Thalmann Market Perform to Underperform $13.00 to $5.00
2016-05-02 Upgrade Oppenheimer Market Perform to Outperform $60.00
2016-05-02 Downgrade Leerink Swann Market Perform to Underperform $13.00 to $5.00
2016-05-02 Reiterated Rating WBB Securities Strong-Buy $40.00
2016-05-02 Downgrade Leerink Partner Market Perform to Underperform
2016-04-29 Downgrade Jefferies Group Hold to Underperform $7.00 to $13.80
2016-04-26 Downgrade Piper Jaffray Neutral to Underweight $15.00 to $6.00
2016-04-26 Lower Price Target Jefferies Group Hold to Hold $14.00 to $7.00
2016-04-26 Downgrade SunTrust Neutral to Reduce $14.00 to $4.00
2016-04-26 Downgrade Oppenheimer Outperform to Market Perform
2016-04-26 Reiterated Rating Janney Montgomery Scott Neutral $15.00
2016-04-26 Reiterated Rating WBB Securities Buy $40.00
2016-04-24 Reiterated Rating Needham & Company LLC Buy $53.00 to $20.00
2016-04-23 Reiterated Rating Cowen and Company Market Perform
2016-04-23 Reiterated Rating RBC Capital Hold
2016-04-23 Reiterated Rating Robert W. Baird Buy $47.00 to $23.00
2016-04-22 Boost Price Target RBC Capital Sector Perform $7.50 to $14.00
2016-04-21 Reiterated Rating Piper Jaffray Neutral to Hold
2016-04-21 Reiterated Rating Leerink Swann Hold $13.00
2016-04-21 Downgrade Wedbush Outperform to Neutral $14.00 to $32.00
2016-04-21 Downgrade William Blair Outperform to Market Perform
2016-04-21 Reiterated Rating Oppenheimer Outperform to Buy $60.00
2016-04-20 Initiated Coverage Janney Montgomery Scott Neutral $19.00
2016-04-19 Reiterated Rating Jefferies Group Hold $14.00
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-04-06 Boost Price Target Oppenheimer Outperform $45.00 to $60.00
2016-03-30 Reiterated Rating WBB Securities Buy $40.00
2016-03-23 Downgrade JMP Securities Market Perform to Underperform $10.00
2016-03-22 Reiterated Rating Jefferies Group Hold $14.00
2016-03-22 Reiterated Rating Needham & Company LLC Buy $53.00
2016-03-22 Reiterated Rating Robert W. Baird Outperform $47.00
2016-03-14 Reiterated Rating Jefferies Group Hold $14.00
2016-03-11 Reiterated Rating Oppenheimer Outperform $45.00
2016-03-10 Reiterated Rating Piper Jaffray Hold
2016-03-09 Reiterated Rating Wedbush Outperform $32.00
2016-03-01 Lower Price Target Needham & Company LLC Buy $55.00 to $53.00
2016-02-27 Reiterated Rating Cowen and Company Hold
2016-02-26 Reiterated Rating Wedbush Outperform $32.00
2016-02-10 Reiterated Rating Oppenheimer Outperform $45.00
2016-02-08 Reiterated Rating Piper Jaffray Hold
2016-02-01 Reiterated Rating Wedbush Outperform $32.00 to $56.00
2016-01-19 Lower Price Target SunTrust Neutral $20.00
2016-01-19 Reiterated Rating Robert W. Baird Outperform $47.00
2016-01-19 Reiterated Rating Wedbush Outperform $56.00
2016-01-19 Downgrade RBC Capital Outperform to Sector Perform $62.00 to $15.00
2016-01-15 Reiterated Rating Leerink Swann Hold
2016-01-15 Reiterated Rating Oppenheimer Buy $45.00
2016-01-15 Reiterated Rating Needham & Company LLC Buy
2016-01-15 Reiterated Rating Cowen and Company Hold
2016-01-15 Downgrade Piper Jaffray Overweight to Neutral $15.00
2016-01-05 Reiterated Rating Piper Jaffray Overweight $48.00
2015-11-28 Reiterated Rating Needham & Company LLC Buy
2015-11-25 Reiterated Rating Robert W. Baird Outperform $47.00
2015-11-25 Reiterated Rating Jefferies Group Hold $28.00 to $38.00
2015-11-22 Reiterated Rating Needham & Company LLC Buy $55.00
2015-11-22 Reiterated Rating WBB Securities Buy $40.00
2015-11-20 Reiterated Rating Oppenheimer Outperform $45.00
2015-11-11 Reiterated Rating Cowen and Company Market Perform
2015-11-08 Reiterated Rating Needham & Company LLC Buy $50.00
2015-11-08 Reiterated Rating Roth Capital Buy $50.00
2015-11-06 Lower Price Target Leerink Swann Market Perform $33.00 to $27.00
2015-10-23 Initiated Coverage Bank of America Buy $49.00
2015-10-23 Initiated Coverage Bank of America Corp. Buy $49.00
2015-10-22 Initiated Coverage Jefferies Group Hold $28.00 to $28.00
2015-10-17 Reiterated Rating Oppenheimer Buy $45.00
2015-10-16 Reiterated Rating Roth Capital Buy $50.00
2015-10-09 Reiterated Rating Oppenheimer Outperform $45.00
2015-10-05 Reiterated Rating Cowen and Company Market Perform
2015-10-04 Reiterated Rating Piper Jaffray Buy
2015-10-02 Reiterated Rating Robert W. Baird Buy $47.00
2015-10-02 Upgrade Wedbush Neutral to Outperform $56.00
2015-10-01 Reiterated Rating Needham & Company LLC Buy $38.00 to $55.00
2015-10-01 Reiterated Rating Roth Capital Buy $50.00
2015-09-30 Reiterated Rating William Blair Buy
2015-09-30 Reiterated Rating RBC Capital Outperform $62.00
2015-09-28 Reiterated Rating Oppenheimer Buy $45.00
2015-09-03 Reiterated Rating Roth Capital Buy $50.00
2015-09-01 Boost Price Target SunTrust Neutral $33.00 to $36.00
2015-09-01 Boost Price Target Susquehanna Neutral $33.00 to $36.00
2015-08-26 Reiterated Rating Cowen and Company Hold
2015-08-26 Reiterated Rating William Blair Buy $43.00
2015-08-26 Reiterated Rating Robert W. Baird Buy $47.00
2015-08-26 Upgrade RBC Capital Sector Perform to Outperform $35.00 to $62.00
2015-08-26 Reiterated Rating Roth Capital Buy $45.00 to $50.00
2015-08-24 Upgrade Piper Jaffray Neutral to Overweight $28.00 to $48.00
2015-08-20 Reiterated Rating Roth Capital Buy $50.00 to $45.00
2015-08-13 Reiterated Rating WBB Securities Buy $35.00 to $40.00
2015-08-07 Reiterated Rating Cowen and Company Hold
2015-08-07 Reiterated Rating Robert W. Baird Buy $34.00 to $47.00
2015-08-07 Reiterated Rating RBC Capital Hold $20.00 to $35.00
2015-08-07 Boost Price Target Wedbush Neutral $25.00 to $31.00
2015-08-07 Downgrade SunTrust Buy to Neutral $33.00
2015-08-06 Reiterated Rating Piper Jaffray Hold
2015-08-05 Reiterated Rating Roth Capital Buy $45.00
2015-07-20 Reiterated Rating Roth Capital Buy
2015-06-30 Reiterated Rating Roth Capital Buy $45.00
2015-06-30 Reiterated Rating Oppenheimer Buy $45.00 to $28.18
2015-06-30 Reiterated Rating Robert W. Baird Buy $34.00
2015-06-18 Reiterated Rating SunTrust Buy $33.00
2015-06-09 Set Price Target RBC Capital Hold $20.00
2015-06-09 Reiterated Rating Roth Capital Buy $45.00
2015-05-23 Reiterated Rating Deutsche Bank Hold $24.00
2015-05-23 Reiterated Rating William Blair Outperform $34.00 to $43.00
2015-05-23 Reiterated Rating Piper Jaffray Neutral $20.00
2015-05-23 Reiterated Rating Deutsche Bank AG Hold $24.00
2015-05-22 Reiterated Rating WBB Securities Strong-Buy $25.00 to $35.00
2015-05-21 Downgrade Bank of America Buy to Neutral $20.00 to $28.00
2015-05-20 Set Price Target Oppenheimer Buy $45.00
2015-05-20 Reiterated Rating Cowen and Company Neutral
2015-05-20 Set Price Target Robert W. Baird Buy $20.00 to $34.00
2015-05-20 Boost Price Target Wedbush Neutral $16.00 to $25.00
2015-05-20 Upgrade Canaccord Genuity Hold to Buy $16.00 to $30.00
2015-05-20 Upgrade SunTrust Neutral to Buy $14.00 to $33.00
2015-05-20 Boost Price Target RBC Capital Sector Perform $15.00 to $20.00
2015-05-20 Boost Price Target Roth Capital Buy $22.00 to $45.00
2015-05-07 Reiterated Rating Needham & Company LLC Buy $38.00
2015-05-06 Upgrade Robert W. Baird Neutral to Outperform $16.00 to $20.00
2015-04-07 Upgrade Roth Capital Buy $22.00
2015-04-07 Upgrade SunTrust Neutral $14.00
2015-04-01 Set Price Target Oppenheimer Buy $45.00
2015-04-01 Set Price Target Robert W. Baird Hold $16.00
2015-04-01 Reiterated Rating RBC Capital Positive
2015-03-02 Lower Price Target Needham & Company LLC Buy $52.00 to $38.00
2015-02-27 Reiterated Rating Canaccord Genuity Hold $16.00
2015-02-27 Reiterated Rating Robert W. Baird Neutral
2015-02-27 Downgrade Cowen and Company Outperform to Market Perform
2015-02-20 Set Price Target Roth Capital Buy $22.00
2015-02-17 Upgrade Bank of America Neutral to Buy $19.00 to $21.00
2015-02-04 Initiated Coverage SunTrust Neutral
2015-01-27 Upgrade Northland Securities Market Perform to Outperform $3.00
2015-01-22 Initiated Coverage RBC Capital Sector Perform $15.00
2015-01-20 Downgrade Wedbush Outperform to Neutral $16.00
2015-01-15 Set Price Target Cowen and Company Buy $19.00
2015-01-15 Reiterated Rating WBB Securities Buy
2015-01-08 Initiated Coverage Canaccord Genuity Hold
2015-01-07 Set Price Target Roth Capital Buy $22.00
2014-11-26 Upgrade WBB Securities Buy to Strong-Buy $25.00
2014-11-03 Initiated Coverage Roth Capital Buy
2014-10-31 Reiterated Rating Robert W. Baird Positive
2014-10-28 Downgrade Robert W. Baird Outperform to Neutral $53.00 to $21.00
2014-10-27 Downgrade Stifel Nicolaus Buy to Hold
2014-10-27 Downgrade JMP Securities Outperform to Market Perform
2014-10-07 Reiterated Rating Credit Suisse Outperform
2014-10-07 Reiterated Rating Credit Suisse Group AG Outperform
2014-09-24 Initiated Coverage Credit Suisse Outperform $36.00
2014-08-19 Initiated Coverage Cowen and Company Outperform $44.00
2014-07-31 Initiated Coverage Oppenheimer Outperform $45.00
2014-07-30 Reiterated Rating Deutsche Bank Positive
2014-07-29 Boost Price Target WBB Securities Speculative Buy to Buy $25.00
2014-07-22 Initiated Coverage Bank of America Neutral $27.00
2014-05-22 Initiated Coverage Roth Capital Buy $52.00
2014-04-22 Boost Price Target Deutsche Bank Positive to Hold $17.00 to $35.00
2014-04-22 Upgrade Citigroup Inc. Sell to Neutral
2014-04-21 Upgrade Canaccord Genuity Hold to Buy $27.00 to $63.00
2014-04-21 Upgrade JMP Securities Market Perform to Outperform $54.00
2014-04-21 Reiterated Rating Needham & Company LLC Buy $36.00 to $52.00
2014-04-21 Upgrade William Blair Market Perform to Outperform $63.00
2014-04-14 Initiated Coverage Sidoti Buy
2014-03-04 Boost Price Target Canaccord Genuity Hold $25.00 to $27.00
2014-01-27 Downgrade JMP Securities Outperform to Market Perform $25.00
2014-01-24 Boost Price Target Canaccord Genuity $20.00 to $25.00
2014-01-21 Upgrade Needham & Company LLC Hold to Buy $36.00
2014-01-06 Downgrade Citigroup Inc. Neutral to Sell $13.00
2013-12-23 Upgrade Piper Jaffray Underweight to Neutral $19.55 to $20.00
2013-12-06 Downgrade Canaccord Genuity Buy to Hold $20.00
2013-11-26 Upgrade WBB Securities Sell to Speculative Buy $9.00 to $19.00
2013-11-13 Lower Price Target Canaccord Genuity Buy $20.00
2013-11-12 Lower Price Target Robert W. Baird Outperform $63.00 to $22.00
2013-11-12 Lower Price Target Leerink Swann Market Perform $44.00 to $17.00
2013-11-12 Lower Price Target Wedbush Outperform $60.00 to $45.00
2013-11-12 Downgrade Deutsche Bank Buy to Hold $71.00 to $17.00
2013-11-12 Lower Price Target FBR & Co. Market Perform $48.00 to $20.00
2013-11-12 Downgrade Janney Montgomery Scott Neutral to Sell
2013-11-12 Downgrade William Blair Outperform to Market Perform
2013-11-12 Downgrade Needham & Company LLC Buy to Hold
2013-11-12 Downgrade Piper Jaffray Overweight to Underweight $58.00 to $20.00
2013-10-30 Initiated Coverage FBR & Co. Market Perform $48.00
2013-10-03 Reiterated Rating Robert W. Baird Buy
2013-09-26 Reiterated Rating Canaccord Genuity Positive to Buy $65.00
2013-09-23 Reiterated Rating Needham & Company LLC Positive
2013-09-20 Upgrade Piper Jaffray Neutral to Overweight
2013-09-20 Upgrade Deutsche Bank Hold to Buy $45.00 to $71.00
2013-04-22 Initiated Needham Buy $57
2013-04-04 Initiated Robert W. Baird Outperform $63
2013-04-03 Initiated Robert W. Baird Outperform $63
2013-03-08 Reiterated Burrill Institutional Research Mkt Outperform $54 to $39
2012-11-26 Initiated Burrill Institutional Research Mkt Outperform $54
2012-09-12 Downgrade WBB Securities Hold to Sell $8 to $9
2012-08-09 Initiated WBB Securities Hold $8
2016-06-27 Reiterated Rating Robert W. Baird Outperform $23.00
2016-06-27 Reiterated Rating William Blair Market Perform
2016-06-25 Reiterated Rating Jefferies Group Underperform $7.00
2016-06-22 Reiterated Rating Wedbush Outperform $36.00
2016-06-21 Reiterated Rating Oppenheimer Outperform $60.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Barry Richard 7.93%  (3245432) SRPT / TELK /
Hudson Leslie Former CEO 0.94%  (384559) SRPT /
INGRAM DOUGLAS S President & CEO 0.93%  (382058) AGN / SRPT /
BEHRENS M KATHLEEN 0.28%  (116534) SRPT /
Kaye Edward M. MD SVP & Chief Medical Officer 0.17%  (71229) CYTK / SRPT /
BOYLE J DAVID II CEO 0.17%  (70282) SRPT /
CHASE ANTHONY R 0.16%  (67194) APC / SRPT / WES /
Price Ben Gil 0.10%  (42830) SRPT /
Mahatme Sandesh Senior Vice President, CFO 0.10%  (42661) AGLE / FLXN / SRPT /
Howton David T SVP, General Counsel 0.08%  (31118) SRPT /
Christopher Nishan Garabedian 0.07%  (29552) SRPT /
Ruff Shamim SVP, Regulatory Affairs & Qual 0.07%  (28809) SRPT /
Cumbo Alexander VP, Head of Commercial 0.06%  (25325) SRPT /
Aphale Jayant SVP Technical Operations 0.03%  (12255) SRPT /
Wigzell Hans Lennart Rudolf 0.02%  (10084) SRPT /
Goolsbee William Alden 0.02%  (8166) SRPT /
JACOBSEN MICHAEL A VP of Finance and PAO 0.02%  (7500) OMER / SRPT /
HODGMAN JOHN 0.02%  (6333) IMMR / ITMN / SRPT /
Nicaise Claude 0.01%  (5418) SRPT /
BONNEY MICHAEL W 0.01%  (3418) ALNY / CBST / CELG / HQH / HQL / NPSP / SRPT /